For many patients, three sessions will provide the results they expect
By week 36, this weight loss effect was even more pronounced, increasing from 9.4% to 14.7%, while the placebo group saw a reduction of only 2.3%
[10,11] In a real-world cohort transitioning off GLP-1 RA therapy to cost-effective medications with weight-lowering effects, metformin was the most frequently utilized agent as maintenance treatment in about 80% patients
Additional weight loss after surgery can affect results, so timing and stability are key to long-lasting outcomes
These therapies not only target weight loss but also address underlying metabolic and hormonal factors that contribute to obesity and aging
Key GLP-1 Access Metrics and Benchmarks These figures illustrate the steep gap between ideal access (near-100% coverage, same-day approvals) and reality (sub-50% fill, multi-day delays)